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Abstract
The contractile state of the human myometrium is controlled by extracellular signals that 
promote relaxation or contraction. Many of these signals function through G protein-
coupled receptors at the cell surface, stimulating heterotrimeric G proteins and leading to 
changes in the activity of effector proteins responsible for bringing about the response. G 
proteins can interact with multiple receptors and many different effectors and are key 
players in the response. Regulators of G protein signalling (RGS) proteins are GTPase 
activating proteins for heterotrimeric G proteins and help terminate the signal. Little is 
known about the function of RGS proteins in human myometrium and we have therefore 
analysed transcript levels for RGS proteins at various stages of pregnancy (non-pregnant, 
preterm, term non-labouring, term labouring). RGS2 and RGS5 were the most abundantly 
expressed isolates in each of the patient groups. The levels of RGS4 and RGS16 (and to a 
lesser extent RGS2 and RGS14) increased in term labouring samples relative to the other 
groups. Yeast two-hybrid analysis and co-immunoprecipitation in myometrial cells 
revealed that both RGS2 and RGS5 interact directly with the cytoplasmic tail of the 
oxytocin receptor, suggesting they might help regulate signalling through this receptor.
Key words: G protein-coupled receptors; labour; myometrium; RGS proteins
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1. Introduction
Initiation of labour involves a change from quiescence to regular, forceful uterine 
contractions. The change is mediated by hormonal, metabolic and intracellular signalling, 
but the regulatory mechanisms underlying this process are poorly understood. 
Information relating to these mechanisms is essential to providing a better understanding 
of disorders associated with human parturition, such as pre-term labour (Lopez-Bernal 
and TambyRaja, 2000). Many of the signalling pathways that regulate contraction and
relaxation of myometrial cells involve G protein-coupled receptors (Europe-Finner et al., 
1997; Plested and Lopez-Bernal, 2001). In the unstimulated state, the receptor is 
associated with a heterotrimeric complex of Gα, G and G subunits in which the Gα
subunit is bound to GDP. Receptor activation stimulates exchange of GDP for GTP, 
releasing the Gα-GTP and G subunits to activate downstream effectors that bring about 
changes in cell behaviour. For example, the oxytocin receptor functions via G proteins 
that activate phospholipase C, thereby increasing inositol trisphosphate (IP3) production, 
leading to increases in intracellular calcium, triggering muscle contraction (Blanks and 
Thornton, 2003). The receptors for prostaglandins, vasopressin and corticotrophin-
releasing factor (CRF) also act via G protein-coupled receptors and G proteins. As many 
G protein-coupled receptors can interact with more than one G protein, and many G 
proteins can activate more than one type of effector protein, the G proteins play a pivotal 
role in integrating the stimulatory and inhibitory signals that regulate contractility.
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G protein signalling ceases when Gα-GTP hydrolysis returns the heterotrimer to its 
inactive state. The slow intrinsic rate of GTP hydrolysis by Gα proteins is regulated by 
interactions with a specific subfamily of GTPase-activating proteins (GAPs) known as 
Regulators of G protein Signalling or RGS proteins (Ross and Wilkie, 2000; Hollinger 
and Hepler, 2002; Xie and Palmer, 2007). Since their discovery in Caenorhabditis 
elegans (Koelle and Horvitz, 1996) and Saccharomyces cerevisiae (Dohlman et al., 
1996), over 30 different RGS proteins have been identified in mammals, many with 
spatiotemporal-specific expression (Abramow-Newerly et al., 2006; Xie and Palmer, 
2007).
There have been several studies into the ability of RGS proteins to regulate contraction in 
cardiomyocytes (Tamirisa et al., 1999; Mittmann et al., 2002; Snabaitis et al., 2005; Hao 
et al., 2006), vascular smooth muscle cells (Tang et al., 2003) and intestinal smooth 
muscle (Hu et al., 2008) but little is known about their role in myometrium. Microarray 
analyses have detected expression of several RGS transcripts in human myometrium and 
a recent study found that expression of RGS12 was upregulated at labour (O’Brien et al.
2008). Earlier studies from Soloff and colleagues showed that RGS2 mRNA levels 
increased in cultured human myometrial cells following stimulation with oxytocin (Park 
et al., 2002) while RGS2 transcription in rats increased dramatically during pregnancy 
before being down-regulated at term (Suarez et al., 2003). However, no investigation of 
the role of RGS2 was undertaken in either system.
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To initiate a more complete understanding of RGS expression in human myometrium, we 
used semi-quantitative polymerase chain reaction (PCR) to analyse transcript levels for 
all of the major RGS proteins at various stages of pregnancy (non-pregnant, preterm, term 
non-labouring, term labouring). Transcripts for many of the RGS proteins were present at 
low level and did not vary throughout pregnancy, although the levels of RGS4 and 
RGS16 (and to a lesser extent RGS2 and RGS14) increased in the term labouring 
samples. RGS2 and RGS5 were the most abundantly expressed isolates in each of the 
patient groups and we sought to further investigate potential roles for these two RGS 
proteins in human myometrium. Yeast two-hybrid analysis and co-immunoprecipitation 
experiments in primary myometrial cells revealed that both RGS2 and RGS5 interact 
directly and specifically with the cytoplasmic tail of the oxytocin receptor. Our results 
suggest a potential role for RGS proteins in regulating signalling in the human 
myometrium.
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2. Materials and Methods
2.1 Subject criteria and selection.
All procedures were conducted within the guidelines of The Declaration of Helsinki and 
were subject to local ethical approval (REC-05/Q2802/107). Myometrial samples were 
collected with informed written consent from the following groups of women: (i) non-
pregnant (aged 38-48 years) undergoing hysterectomy for dysmenorrhoea (ii) preterm 
pregnant women (aged 20-30 years) prior to the onset of labour (“preterm”) (iii) term 
pregnant women prior to labour (“term, non-labouring”) (iv) term pregnant women 
following the onset of labour (“term, labouring”). Labour was defined as regular 
contractions (<3 min apart) plus membrane rupture and cervical dilation (>3 cm) with no 
augmentation. Samples were taken from the upper edge of a lower segment incision at 
Caesarean section from women without underlying disease, for fetal distress, breech 
presentation, previous section, placental praevia, maternal request or failure to progress. 
Non-pregnant biopsies were taken from the upper third of the uterine body, 
approximately 5 mm away from endometrial or serosal surfaces, immediately after 
hysterectomy. Tissue was snap-frozen in liquid nitrogen and stored at -80oC. 
2.2 RNA analysis
Total RNA was extracted from frozen myometrial biopsies (Total RNA Isolation Kit 
RNAEasy; Promega, Southampton, UK) according to the manufacturer’s instructions. 
RNA was reverse transcribed into complementary DNA (cDNA) for use as a template for 
amplification by the polymerase chain reaction (PCR) by using 500 ng total RNA 
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samples, random hexamers (N6) (Pharmacia Amersham Life Sciences, Little Chalfont, 
UK) and 10 IU/µl RNase H- Reverse Transcriptase Superscript II (Gibco BRL Life 
Technologies, Paisley, UK). Complementary DNA from the reaction was used in the 
amplification reaction. PCR was carried out with oligonucleotide primers specific for 
each RGS. The sequence for each pair of sense and anti-sense primers, corresponding to 
the open reading frame of each of human RGSs (RGS1 to RGS16) and the size of the 
expected PCR product are listed in Table 1. We did not screen for RGS8 as it is brain 
specific (Koelle and Horvitz, 1996; Saitoh et al., 1997), and RGS15 is a splice variant of 
RGS3 (Druey et al., 1996; Chatterjee et al., 1997).
PCR was performed in 25 µl reactions using 10 µCi/µl [32P]-labelled α-dGTP and 5 IU/µl 
TAQ DNA polymerase (Gibco BRL Life Technologies). Amplifications were carried out 
as follows: an initial denaturation step of 5 min at 94oC followed by 27 to 30 cycles of 
denaturation at 94oC for 1 min, annealing at 55oC to 60oC for 1 min, and elongation at 
72oC for 1 min, followed by a final extension at 72oC for 10 min. PCR products were 
separated by electrophoresis on a 6% polyacrylamide gel and the dried gel exposed to X-
ray film (Fuji Photo Film Co. Ltd., Tokyo, Japan) or to a phosphorimager screen 
(Molecular Dynamics, Pharmacia Amersham Life Sciences, Little Chalfont, UK) for 
quantification purposes. Radioactivity peaks for each product were determined using 
ImageQuant (IQ) (Molecular Dynamics, Pharmacia Amersham Life Sciences).
PCR products were purified using the Geneclean II Kit (Amersham, Luton, UK) and 
ligated into the EcoRI restriction site of pCR-TOPO vector (Invitrogen BV, Croningen, 
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Netherlands) using TOPO TA Cloning Kit (Invitrogen BV). The vector was used to 
transform DH5α strain of Escherichia coli and plasmids isolated using the QIAprep Spin 
Plasmid Kit (Qiagen, Crawley, Sussex, UK). PCR products obtained for human RGS1 to 
RGS16 were sequenced by the di-deoxynucleotide method with double-stranded DNA as 
template.
2.3 Expression analysis
All PCR reactions were performed in triplicate. The amount of PCR product for each 
RGS mRNA was compared to the product obtained using primers for calponin. The 
mRNA levels of calponin do not change with or throughout pregnancy and calponin was 
used as a housekeeping gene for normalisation of the cDNA input (Brodt-Eppley and 
Myatt, 1999; Moore et al., 1999). In order to validate the semi-quantitative nature of the 
technique, PCR reactions were also performed with 50% of the original cDNA 
concentration as template. Results are expressed as mean ±SE. Comparison between 
sample sets was by one-way ANOVA with Tukey’s multiple comparison test. 
Differences were considered significant at P<0.05 level. All analysis was performed with 
GraphPad Prism version 4.03 (GraphPad Software Inc, San Diego, CA, USA).
2.4 Yeast two-hybrid screening
The AH109 Saccharomyces cerevisiae strain and vectors were supplied with the 
Matchmaker yeast two-hybrid kit (BD Biosciences Clontech, Oxford, UK). The region 
encoding the C-terminal cytoplasmic domains of the oxytocin receptor (from residue 
Gly334) and the CRF receptor 1a (from residue Val370) were amplified by PCR and cloned 
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into pGBKT7 to produce in-frame translational fusions to the GAL4 Binding Domain. 
The coding regions for full length RGS1, RGS2 and RGS5 were amplified by PCR using 
the primers in Table 1 and cloned into pGADT7 to produce in-frame translational fusions 
to the GAL4 Activation Domain. Two-hybrid assays were carried out following 
sequential transformations of AH109 with pGBKT7-based plasmids and then pGADT7-
based plasmids. Co-transformants were maintained on MM (a defined minimal medium
lacking leucine and tryptophan) and immunoblotting was used to confirm that the various 
fusion proteins were expressed. Cell concentrations were determined using a Coulter 
Channelyser (Beckman-Coulter, Luton, UK). Experiments to investigate interactions and 
protein expression were repeated at least three times with different isolates.
2.5 Protein analysis in myometrial cells
Myometrial tissue samples were digested at 37oC for 30 min in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 1 mg/ml collagenase 1A and 1 mg/ml collagenase 
XI (Sigma-Aldrich, Poole, UK). Cells were dissociated by triturating through a Pasteur 
pipette , filtered through a 45-µm filter and further digestion stopped by adding 10% fetal 
calf serum (FCS) (Invitrogen Life Technologies, Paisley, UK) in DMEM. Following 
centrifugation (450 g for 15 min), cells were resuspended in DMEM supplemented with 
10% FCS, L-glutamine, penicillin-streptomycin (100 U/ml) and amphotericin B (2 
µg/ml) and grown at 37oC in 5% CO2. The purity of myocycte cultures was routinely 
assessed using α-actin and calponin monoclonal antibodies as described previously (Tribe 
et al., 2000). All experiments in this study were performed with myometrial cells between 
1 and 4 passages. Cells were resuspended in lysis buffer (25 mM Hepes pH7.5, 150 mM
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NaCl, 3 mM EDTA, 3 mM EGTA, 1 mM sodium orthovanadate, 50 mM NAF, 0.5% w/v 
Triton X-100) and insoluble material removed by centrifugation (10,000 g for 15 min). 
Precipitating antibody, or preimmune serum, was added and incubated at 4oC for 4 h 
before addition of protein G-Sepharose beads (Sigma-Aldrich). The mixture was 
incubated with rotation overnight at 4oC. Beads were collected by centrifugation, washed, 
and the proteins eluted in sample buffer (50 mM Tris-HCl pH 6.8, 8% v/v glycerol, 1% 
w/v SDS and 2% v/v -mercaptoethanol) before being resolved by SDS-PAGE on a 12% 
polyacrylamide gel. Following separation, proteins were transferred to a polyvinylidene 
fluoride (PVDF) membrane (Bio-Rad, Hemel Hempstead, Hants, UK) soaked in Towbin 
buffer (25 mM Tris, 192 mM glycine, 0.1% w/v SDS, 10% v/v methanol) using a Semi-
Phor Transfer Dry Blotting Unit (Hoefer Scientific Instruments, San Francisco, CA, 
USA) run at 65 mV for 30 min. Non-specific binding sites were blocked using 5% low-
fat milk powder in TST (10 mM Tris-HCl pH 7.5, 100 mM NaCl and 0.05% v/v Tween-
20) for 90 min. Antibodies were used according to their manufacturer’s instructions; 
rabbit anti-CRFR1, rabbit anti-OTR, rabbit anti-RGS2 and goat anti-RGS5 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), HRP-conjugated donkey anti-sheep (Sigma-
Aldrich) and HRP-conjugated donkey anti-rabbit (Amersham plc, Little Chalfont, UK). 
The blot was incubated with primary antibody for 1 h, washed, and incubated with the 
secondary antibody for 1 h. Chemiluminescent signals were detected using the ECL 
detection reagent (Amersham plc).
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3. Results
3.1 Expression of RGS1-RGS16 mRNA in human myometrium
Semi-quantitative RT-PCR was used to analyse RGS mRNA expression in different 
samples of human myometrium, and the results compared to the mRNA levels of 
calponin (Fig. 1). The mRNA level of calponin do not change with or throughout 
pregnancy (Brodt-Eppley and Myatt, 1999; Moore et al., 1999), providing an appropriate 
mechanism to control or indicate standardising the study. Nucleotide sequencing 
confirmed that the PCR products corresponded to the expected RGS targets (not shown).
A comparison of RGS expression levels for the different pregnancy states is shown in 
Fig. 2. RGS2 and RGS5 were the most abundantly expressed mRNAs in each of the 
patient groups, but we also detected transcripts for RGS1, RGS4, RGS9, RGS10, RGS12, 
RGS13, RGS14 and RGS16. Expression of RGS4 and RGS16, and to a lesser extent 
RGS14, increased in the term labouring samples compared to all other sample groups. 
Expression of RGS2 was also increased in the term labouring samples relative to the 
preterm and term non-labouring samples, but was not significantly increased relative to 
the non-pregnant group.
3.2 Interactions of RGS proteins with G protein-coupled receptors
RGS proteins are divided into subfamilies based on sequence homology and RGS2 and 
RGS5 (as well as RGS4 and RGS16) belong to the R4 family (Abramow-Newerly et al., 
2006; Bansal et al., 2007). The R4 family members are the smallest and best 
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characterised of the RGS proteins. They are generally non-discriminatory in vitro and act 
as GAPs on both Gαq/11 and Gαi/o (De Vries et al., 2000). In contrast, they display 
much greater specificity in intact cells and it has been suggested that part of this 
specificity is due to direct interactions between the RGS proteins and their target 
receptors (reviewed by Neitzel and Hepler, 2006). RGS proteins have been documented 
to bind to G protein-coupled receptors through direct interactions with either the 
intracellular third (i3) loop (Zeng et al., 1998; Hepler, 2003; Bernstein et al., 2004; Hague 
et al., 2005) or with the C-terminal tail (Snow et al., 1998; Georgoussi, et al., 2006; 
Ballon et al., 2006; Langer et al., 2008) of the receptor. The increased expression of 
RGS2 in cultured human myometrial cells following exposure to oxytocin (Park et al., 
2002) is consistent with a role for RGS2 in regulating the myometrial response to 
oxytocin and we sought to investigate whether RGS2, and RGS5, interact directly with 
the oxytocin receptor. Our initial experiments utilised the C-terminal tail of the oxytocin 
receptor since it has been well documented that many G protein-coupled receptors
accessory proteins (e.g. arrestins and G protein-coupled receptor kinases) bind to this 
region of receptors (reviewed by Milligan and White, 2001).
The yeast two-hybrid system monitors direct interactions between two proteins, or 
protein domains (Li and Fields, 1993). Expression of full-length G protein-coupled 
receptors in this system is complicated by the hydrophobic transmembrane domains and 
we therefore expressed the C-terminal cytoplasmic tails of the receptors as translational
fusions to the GAL4 Binding Domain (Fig. 3). RGS2 and RGS5 are soluble proteins and 
were expressed as fusions to the GAL4 Activation Domain. Yeast transformants 
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expressing each RGS-receptor combination were plated on MM (a defined minimal 
medium that lacks leucine and tryptophan) to confirm the presence of the two test 
plasmids, and on MM-His-Ade+XαGal (MM lacking histidine and adenine, but 
supplemented with 5-bromo-4-chloro-3-indoyl-α-D-galactoside) to investigate potential 
interactions. Control strains expressing the strongly interacting SV40-T antigen and p53, 
or the non-interacting SV40-T antigen and lamin-C, were included for comparison.
Interaction between the two target proteins recombines the GAL4 Binding and Activation 
Domains, leading to expression of the HIS3, ADE2 and MEL1 reporter genes and the 
formation of blue colonies on the test plates. The results suggest an interaction between 
the oxytocin receptor and both RGS2 and RGS5 (Fig. 3). We were unable to observe any 
interaction between the i3 loops of either the oxytocin receptor or the CRF receptor with 
the RGS proteins tested (data not shown). To provide a more quantitative measurement of 
the strength of the interactions, liquid-based -galactosidase assays were performed on all 
transformants to measure expression of the LacZ reporter gene. Under the conditions 
used, a strong interaction between two proteins (such as SV40-T antigen and p53) 
generates ~4.5 Units of -galactosidase activity, while two non-interacting proteins (such 
as SV40-T antigen and lamin C) generate less than 0.5 Units. Strains expressing the 
oxytocin receptor generated more than 3 Units of activity with both RGS2 and RGS5, 
suggesting strong interactions. The lack of interaction between the oxytocin receptor and 
RGS1, and between any of the RGS proteins and the CRF receptor, suggests that the 
interactions of the oxytocin receptor with RGS2 and RGS5 are specific.
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The yeast two-hybrid data indicated that the oxytocin receptor interacted with both RGS2 
and RGS5, and we sought to determine whether these proteins also interacted in human 
myometrial cells. Immunoblotting demonstrated expression of the oxytocin receptor, 
CRF receptor, RGS2 and RGS5 in human primary myometrial cells (Fig. 4). To 
investigate co-immunoprecipitation of RGS proteins with G protein-coupled receptors, 
cell extracts were incubated with a pre-immune antibody or antibodies specific for the 
oxytocin or CRF receptors and immunocomplexes recovered on protein G-Sepharose 
beads, eluted in sample buffer, and resolved by SDS-PAGE. Samples were transferred to 
a PVDF membrane and probed with antibodies to either RGS2 or RGS5. 
Immunocomplexes isolated using the antibody to the oxytocin receptor contained both 
RGS2 and RGS5, indicating that these proteins probably interact within intact cells (Fig.
4). In contrast, neither RGS2 nor RGS5 were present in immunocomplexes isolated using 
the antibody to the CRF receptor.
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4. Discussion
We report the first comprehensive analysis of RGS expression in human myometrium at 
different stages of pregnancy. RGS2 and RGS5 were highly expressed in all samples, 
while expression of RGS4, RGS14 and RGS16 increased in the term labouring samples. 
RGS2 levels were higher in the term labouring samples than in the preterm and term non-
labouring samples, although it was also relatively high in the non-pregnant sample.
Transcripts for RGS1, RGS9, RGS10, RGS12 and RGS13 were detected at low levels in 
all samples.
A recent microarray analysis comparing transcriptional profiles of human myometrium at 
term pregnancy compared with that at labour observed a >5-fold increase in RGS12 
mRNA in the labouring sample (expression levels for the other RGS proteins were not 
reported) (O’Brien et al., 2008). Why this is different to our findings for RGS12 remains
unclear. The only other analysis of RGS expression in myometrium considered only
RGS2, showing an increase in mRNA levels in cultured human myometrial cells 
following stimulation with oxytocin (Park et al., 2002), and an increase in mRNA levels 
during pregnancy in rats (Suarez et al., 2003). Although of interest, neither study is 
directly comparable to our results on RGS expression.
Our observations that RGS2, RGS4, RGS14 and RGS16 are increased in the term 
labouring samples are particular interesting given the potential physiological roles that 
these RGS proteins may play within cells. It has been documented that RGS2, RGS4 and 
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RGS16 all negatively regulate signalling mediated by Gαq/11 and Gαi/o (Hepler, 2003; 
Willars, 2006; Ladds et al., 2007). Given that the oxytocin receptor has been shown to 
couple to both these classes of G protein (Sanborn et al., 1995; Phaneuf et al., 1995), it is 
tempting to speculate that the up regulation of these RGS proteins is required to terminate 
the labouring process. Further, evidence has emerged that some RGS proteins play 
positive regulatory roles within signalling. For example, it has been demonstrated that 
expression of RGS proteins can significantly increase the receptor-stimulated activation 
of both K+ and Ca2+ channels (Tinker, 2008). It is therefore plausible to suggest that the 
up regulation, at term, of these RGS proteins, results in increased flux of Ca2+ ions 
thereby potentially promoting uterine contractions. Further studies, utilising RGS proteins 
with modified activities, (either dominant negative (Bansal et al., 2007) or gain-of-
function (Hill et al., 2008)) will be required to elucidate the precise role that each RGS 
protein performs in the labouring process.
RGS2 and RGS5 belong to the R4 subfamily of RGS proteins (Abramow-Newerly et al., 
2006), members of which are believed to interact directly with their target receptors (Xu 
et al., 1999; Wang et al., 2002; Cho et al., 2003; Benians et al., 2005). Yeast two-hybrid 
analysis and co-immunoprecipitation using extracts from primary myometrial cells 
confirmed that both RGS2 and RGS5 interacted with the oxytocin receptor. Neither 
RGS2 nor RGS5 interacted with the CRF receptor. Although there are several reports of 
the interaction of RGS2 with various G protein-coupled receptors (Hepler, 2003; Zeng et 
al., 1998; Bernstein et al., 2004; Hague et al., 2005), we believe this is the first time that 
RGS5 has been shown to interact directly with a receptor.
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The interaction between RGS2 and the oxytocin receptor is particularly encouraging
given that expression of RGS2 is upregulated in response to stimulation with oxytocin 
(Park et al., 2002). Taken together, the results are very suggestive that RGS2 may be 
important in regulating the myometrial response to oxytocin. A similar proposal could 
also be made for RGS5, and it will be interesting to discover if any of the other RGS 
proteins expressed in the myometrium also interact with G protein-coupled receptors. 
Another challenge will be to investigate whether these interactions have any consequence 
on the contractile state of the human myometrium.  We are encouraged by their ability to 
regulate contraction in cardiomyocytes (Tamirisa et al., 1999; Mittmann et al., 2002; 
Snabaitis et al., 2005; Hao et al., 2006), vascular smooth muscle cells (Tang et al., 2003) 
and intestinal smooth muscle (Hu et al., 2008).
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Figure and Table legends
Fig. 1 RGS expression in human myometrium
Semi-quantitative RT-PCR was used to monitor expression of RGS1 to RGS16 in human 
myometrium.  The expression of each RGS protein was compared to that of calponin, an 
internal standard which remains unchanged with and during pregnancy. Profiles from the 
four different study groups are shown: non-pregnant (n=4); pregnant preterm (n=4, w 
indicates the duration of the pregnancy in weeks), term pregnant non-labouring (n=5) 
term pregnant labouring (n=5). Patients’ numbers are show for reference. The results 
shown are the means of three independent determinations.
Fig. 2 RGS expression at different stages of pregnancy
Expression levels for the various RGS proteins in the different sample groups (expressed 
as mean ±SE) were analysed by one-way ANOVA with Tukey’s multiple comparison 
test.  Differences were considered significant as follows; * P<0.05, ** P<0.01, *** 
P<0.005.
Fig. 3 Two-hybrid analysis of RGS-G protein-coupled receptor interactions
Various combinations of RGS proteins (expressed from pGADT7) and the C-terminal 
cytoplasmic tail regions of the oxytocin receptor (OTR) or corticotrophin releasing factor 
receptor 1a (CRFR) (expressed from pGBKT7) were analysed in the yeast two-hybrid 
system.  All transformants grew on MM, but only those containing interacting proteins 
are able to grow on MM-His-Ade+XαGal, suggesting an interaction between the oxytocin 
receptor and both RGS2 and RGS5. A liquid-based -galactosidase assay provided a 
quantitative measure of the strength of the various interactions. The results are shown as 
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means ±SE of triplicate determinations. Strains expressing the strongly interacting 
combination of SV40-T antigen and p53, and the non-interacting combination of SV40-T 
antigen and lamin-C were included for comparisons.
Fig. 4 RGS2 and RGS5 interact with the oxytocin receptor in human 
myometrial cells
(A) Protein extracts generated from human primary myometrial cells were resolved by 
SDS-PAGE and immunoblot analysis confirmed expression of the CRF receptor (CRFR), 
oxytocin receptor (OTR), RGS2 and RGS5. (B) The cell extracts from A were incubated 
with a preimmune antibody or antibodies specific for the CRF receptor (anti-CRFR) or 
oxytocin receptor (anti-OTR), and immunocomplexes recovered on protein G-Sepharose 
beads, eluted in sample buffer, and resolved by SDS-PAGE. Immunoblot analysis 
confirmed the presence of RGS2 and RGS5 in the extracts (track labelled ‘lysate’) and 
revealed co-immunoprecipitation of RGS2 and RGS5 with the oxytocin receptor but not 
the CRF receptor.
Table 1 Oligonucleotide primer sequences for human RGS1 to RGS16
Sequences for the Sense (S) and Antisense (A) primers for each RGS protein are shown 
with upper case letters representing sequences from within each RGS target and lower 
case letters representing sequences included to allow cloning of the PCR products. 
Accession numbers (Acc No) are given for each RGS, and the expected sizes of the 
various PCR products.
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Table 1 Oligonucleotide primer sequences for human RGS1 to RGS16
RGS Acc No Primer 
name
Primer sequence Size (bp)
RGS1 X73427.1 JO910 (S)
JO911 (A)
ggggatccgtATGCCAGGAATGTTCTTCTCTGC
ggggatccTCACTTTAGGCTATTAGCCTGC
591
RGS2 L13391 JO1339 (S)
JO1340 (A)
ggggatccgtATGCAAAGTGCTATGTTCTTGGC
ggggatccTCATGTAGCATGAGGCTCTGTGG
636
RGS3 U27655 JO915 (S)
JO916 (A)
ggggatccCTAAAGCGGGGGACTCATCTTC
ggggatccaccATGCACCACCTTTCCCTCTTC
620
RGS4 U27768 JO917 (S)
JO918 (A)
ggggatccgtATGTGCAAAGGGCTTGCAGGTC
ggggatccTTAGGCACACTGAGGGACCAG
618
RGS5 AF030108 JO1314 (S)
JO1315 (A)
gggggatccgtATGTGCAAAGGACTTGCAGC
gggggatccCTACTTGATTAACTCCTGATAAAACT
546
RGS6 O75576 JO1316 (S)
JO1318 (A)
gggggatccgtATGGCTCAAGGGTCCGGGGATC
gggggatccTCAGGGCCTCTTAGCGAGTGG
513
RGS7 U32439 JO1319 (S)
JO1320 (A)
gggggatccGCCACCTGACCCTTCTAACCCATG
gggggatccTTAGTAAGACTGAGCAAGGCTTG
516
RGS9 AF071476 JO1321 (S)
JO1322 (A)
gggggatccgtATGACAATCCGACACCAAGGCC
gggggatccATCGGTGCACCAGCCAGTATGCC
577
RGS10 AF045229 JO1324 (S)
JO1325 (A)
gggggatccgtATGGAACACATCCACGACAGCG
gggggatccTCATGTGTTATAAATTCTGGAAGC
504
RGS11 AB016929 JO1326 (S)
JO1327 (A)
gggagatctgtATGGCCGCCGGCCCCGCGCCG
gggagatctCCTGGCACGCAATGACCAGCCTG
523
RGS12 O14924 JO1329 (S)
JO1330 (A)
gggggatCCTGCGTGAGAGGAGGGTCGCCAGC
gggggaTCCGCTTCTTCTCGCTGTCCTC
571
RGS13 O14921 JO1333 (S)
JO1334 (A)
gggggatccgtATGAGCAGGCGGAATTGTTGGATTT
gggggatccTCAGAAACTGTTGTTGGACTGC
480
RGS14 O43566 JO1335 (S)
JO1336 (A)
gggggatcCATGTTTCGGGCACAGCAGCTTCAG
gggggatcCATGTCTCGGATGGTGAGGCCAGG
523
RGS16 O15492 JO1337 (S)
JO1338 (A)
gggggatccaCCATGTGCCGCACCCTGGCCGCC
gggggatcCTCAGGTGTGTGAGGGCTCGTCC
612
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